The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted. The response of the Company is enclosed.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
NSE had asked Supriya Lifescience to explain why segment details were missing from its quick results for the quarter ended December 31, 2025, which were originally filed on February 9, 2026. The company clarified that it operates in only one business segment — Pharmaceuticals — and had selected the 'Single Segment' option during submission, but the data did not display due to a technical glitch. Management called the omission inadvertent, apologized, and said it will look into the error. The company stressed that it has a clean track record of timely and accurate disclosures and remains committed to SEBI compliance.
This is a routine administrative clarification with no financial or operational impact on the business. Investors are unlikely to see any meaningful stock movement, as the issue is a minor technical filing error rather than a compliance breach or penalty.